Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2259

Within days of each other back in 1998, two teams published the results of the first real-world quantum computations. But the first quantum computers weren’t computers at all. They were biochemistry equipment, relying on the same science as MRI machines.

You might think of quantum computing as a hyped-up race between computer companies to build a powerful processing device that will make more lifelike AI, revolutionize medicine, and crack the encryption that protects our data. And indeed, the prototype quantum computers of the late 1990s indirectly led to the quantum computers built by Google and IBM. But that’s not how it all began—it started with physicists tinkering with mathematics and biochemistry equipment for curiosity’s sake.

Read more

The growing understanding of the link between the gut and brain inflammation is perhaps one of the most exciting new avenues in modern medical research. An incredible new study from researchers at the University of Toronto and UC San Francisco has provided a novel insight into the gut-brain connection, revealing the intestine may be the source of immune cells found to reduce brain inflammation in multiple sclerosis (MS) sufferers.

Read more

Popular spit-in-a-tube genetics-testing companies like Ancestry and 23andMe can — and frequently do — sell your data to drugmakers. But on Wednesday, one of those partnerships became much more explicit, when the pharmaceutical giant GlaxoSmithKline announced it was acquiring a $300 million stake in 23andMe.

As part of a four-year deal between the two companies, GlaxoSmithKline will comb 23andMe’s genetic data to look for new drugs to develop, also referred to as drug targets. It will also use the genetic data to inform how patients are selected for clinical trials.

If that news has you thinking about how your own genetic material is being used for research, know that though the DNA you submit to these services is ostensibly anonymized, leaks can happen, and privacy advocates say that such incidents could allow your data to find its way elsewhere, perhaps without your knowledge.

Read more

In this interview, Dr. Leonid Peshkin offers insights on aging, the pitfalls of excessive optimism, and the role of machine learning in studying age-related disease.

Determined but not complacent, grounded but hopeful, Dr. Leonid Peshkin is one of the scientists working on understanding aging so that it may one day be treated like we treat any other ailment.

As he revealed in an interview with the Boston Globe in mid-2018, the idea of having to lose oneself and one’s loved ones to aging never made any sense to him, and ever since he was a child, he has been preoccupied with aging and the fear that it might take away his father, who was almost 60 when Leon was 10 and, sadly, passed away in July 2018 at the age of 96.

Dr. Peshkin, a 48-year-old from Moscow, Russia, possesses a master’s degree in applied mathematics and a Ph.D. in machine learning. He currently works at the Systems Biology Department at Harvard Medical School; his primary interests are embryology, evolution, and aging, which he has studied for over a decade.

Continue reading “An Interview with Dr. Leonid Peshkin” | >

We had no shortage of blood pressure medication recalls in 2018, with multiple companies issuing warnings over drug impurities that could cause cancer. It looks like that trend will continue in 2019 as yet another company has issued a recall of blood pressure tablets after detecting an impurity that may be cancer-causing.

This time around it’s Aurobindo Pharma USA Inc, which is recalling prescriptions of the drug Valsartan, you may remember, has been the subject of recalls due to such impurities in the past. The drug is sold by several manufacturers, and in July of 2018 almost a half-dozen companies were forced to recall their products due to the discovery of human carcinogens in the tablets.

Read more

Drive an hour north of Google’s headquarters up to Oyster Point, south San Francisco, and you will find the office of Calico Labs. The steel and glass building has none of the showmanship of its sister company, with its colourful, attention-grabbing Googleplex campus.

Its name is an acronym for “California Life Company” but its lifeless exterior makes it easy to imagine it being named after another Calico – an abandoned mining town further down the Pacific Coast. The company, a division of Google’s parent company Alphabet, is now five years old, but its operations remain highly secretive.


University of Arizona biomedical engineering professor Philipp Gutruf is first author on the paper Fully implantable, optoelectronic systems for battery-free, multimodal operation in neuroscience research, published in Nature Electronics.

Optogenetics is a biological technique that uses light to turn specific neuron groups in the on or off. For example, researchers might use to restore movement in case of paralysis or, in the future, to turn off the areas of the brain or spine that cause pain, eliminating the need for—and the increasing dependence on—opioids and other painkillers.

“We’re making these tools to understand how different parts of the brain work,” Gutruf said. “The advantage with optogenetics is that you have cell specificity: You can target specific groups of neurons and investigate their function and relation in the context of the whole brain.”

Read more

Dear friends of healthy longevity, yet another year has gone by. Hold back the melancholy though, because in this day and age a passing year can be looked at as a year fewer to wait before rejuvenation biotechnologies are available, rather than a year taken from your healthy lifespan. Busy as we are with all the errands of daily life, it is easy to forget all that’s happened and the progress we’ve made in the field in one year. So while we wait for 2019, let’s take a look back at what 2018 has brought us.

Read more